Ongoing and future clinical studies with appropriate patient selection based on biomarkers detected by state-of-the-art methods may provide the evidence needed to optimize individualized therapeutic strategies and thus further improve the outcome of ER+/HER2− ABC patients. The gene discussed is ERBB2; the disease is aneurysmal bone cyst.